Literature DB >> 19091977

Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Manuel D Galvan1, Sabina Luchetti, Adrian M Burgos, Hal X Nguyen, Mitra J Hooshmand, Frank P T Hamers, Aileen J Anderson.   

Abstract

Although studies have suggested a role for the complement system in the pathophysiology of spinal cord injury (SCI), that role remains poorly defined. Additionally, the relative contribution of individual complement pathways in SCI is unknown. Our initial studies revealed that systemic complement activation was strongly influenced by genetic background and gender. Thus, to investigate the role of the classical complement pathway in contusion-induced SCI, male C1q knock-out (KO) and wild-type (WT) mice on a complement sufficient background (BUB) received a mild-moderate T9 contusion injury with the Infinite Horizon impactor. BUB C1q KO mice exhibited greater locomotor recovery compared with BUB WT mice (p<0.05). Improved recovery observed in BUB C1q KO mice was also associated with decreased threshold for withdrawal from a mild stimulus using von Frey filament testing. Surprisingly, quantification of microglia/macrophages (F4/80) by FACS analysis showed that BUB C1q KO mice exhibited a significantly greater percentage of macrophages in the spinal cord compared with BUB WT mice 3 d post-injury (p<0.05). However, this increased macrophage response appeared to be transient as stereological assessment of spinal cord tissue obtained 28 d post-injury revealed no difference in F4/80-positive cells between groups. Stereological assessment of spinal cord tissue showed that BUB C1q KO mice had reduced lesion volume and an increase in tissue sparing compared with BUB WT mice (p<0.05). Together, these data suggest that initiation of the classical complement pathway via C1q is detrimental to recovery after SCI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091977      PMCID: PMC2680920          DOI: 10.1523/JNEUROSCI.2823-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  106 in total

1.  Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury.

Authors:  Xiang-min Peng; Zhi-gang Zhou; Joseph C Glorioso; David J Fink; Marina Mata
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

Review 2.  Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.

Authors:  Horea Rus; Cornelia Cudrici; Florin Niculescu; Moon L Shin
Journal:  J Neuroimmunol       Date:  2006-08-14       Impact factor: 3.478

3.  Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury.

Authors:  Alun Ackery; Sherri Robins; Michael G Fehlings
Journal:  J Neurotrauma       Date:  2006-05       Impact factor: 5.269

4.  Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression.

Authors:  J David Clark; Yanli Qiao; Xiangqi Li; Xiaoyou Shi; Martin S Angst; David C Yeomans
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

5.  Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains.

Authors:  D Michele Basso; Lesley C Fisher; Aileen J Anderson; Lyn B Jakeman; Dana M McTigue; Phillip G Popovich
Journal:  J Neurotrauma       Date:  2006-05       Impact factor: 5.269

6.  Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma.

Authors:  Fei Qiao; Carl Atkinson; Hongbin Song; Ravinder Pannu; Inderjit Singh; Stephen Tomlinson
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

7.  Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells.

Authors:  Yuqin Yin; Michael T Henzl; Barbara Lorber; Toru Nakazawa; Tommy T Thomas; Fan Jiang; Robert Langer; Larry I Benowitz
Journal:  Nat Neurosci       Date:  2006-05-14       Impact factor: 24.884

8.  Generation of C5a in the absence of C3: a new complement activation pathway.

Authors:  Markus Huber-Lang; J Vidya Sarma; Firas S Zetoune; Daniel Rittirsch; Thomas A Neff; Stephanie R McGuire; John D Lambris; Roscoe L Warner; Michael A Flierl; Laszlo M Hoesel; Florian Gebhard; John G Younger; Scott M Drouin; Rick A Wetsel; Peter A Ward
Journal:  Nat Med       Date:  2006-05-21       Impact factor: 53.440

9.  The membrane attack complex of the complement system is essential for rapid Wallerian degeneration.

Authors:  Valeria Ramaglia; Rosalind Helen Mary King; Michelle Nourallah; Ruud Wolterman; Rosalein de Jonge; Marja Ramkema; Miriam Ann Vigar; Sandra van der Wetering; Brian Paul Morgan; Dirk Troost; Frank Baas
Journal:  J Neurosci       Date:  2007-07-18       Impact factor: 6.167

10.  Role of spinal microglia in rat models of peripheral nerve injury and inflammation.

Authors:  Anna K Clark; Clive Gentry; Elizabeth J Bradbury; Stephen B McMahon; Marzia Malcangio
Journal:  Eur J Pain       Date:  2006-03-20       Impact factor: 3.931

View more
  39 in total

1.  Targeted modulation of the neuroinflammatory response after spinal cord injury: the ongoing quest for the "holy grail".

Authors:  Philip F Stahel; Michael A Flierl
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

2.  Complement protein C1q modulates neurite outgrowth in vitro and spinal cord axon regeneration in vivo.

Authors:  Sheri L Peterson; Hal X Nguyen; Oscar A Mendez; Aileen J Anderson
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

Review 3.  Myelin as an inflammatory mediator: Myelin interactions with complement, macrophages, and microglia in spinal cord injury.

Authors:  Timothy J Kopper; John C Gensel
Journal:  J Neurosci Res       Date:  2017-07-11       Impact factor: 4.164

4.  Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2.

Authors:  Faith H Brennan; Trisha Jogia; Ellen R Gillespie; Linda V Blomster; Xaria X Li; Bianca Nowlan; Gail M Williams; Esther Jacobson; Geoff W Osborne; Frederic A Meunier; Stephen M Taylor; Kate E Campbell; Kelli Pa MacDonald; Jean-Pierre Levesque; Trent M Woodruff; Marc J Ruitenberg
Journal:  JCI Insight       Date:  2019-05-02

5.  Delayed post-injury administration of C5a improves regeneration and functional recovery after spinal cord injury in mice.

Authors:  Q Guo; J Cheng; J Zhang; B Su; C Bian; S Lin; C Zhong
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

6.  The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury.

Authors:  Fei Qiao; Carl Atkinson; Mark S Kindy; Anandakumar Shunmugavel; B Paul Morgan; Hongbin Song; Stephen Tomlinson
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

7.  The Ryk receptor is expressed in glial and fibronectin-expressing cells after spinal cord injury.

Authors:  Pau González; Carmen María Fernández-Martos; Ernest Arenas; Francisco Javier Rodríguez
Journal:  J Neurotrauma       Date:  2013-05-09       Impact factor: 5.269

8.  B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice.

Authors:  Daniel P Ankeny; Zhen Guan; Phillip G Popovich
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

9.  Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury.

Authors:  Sabina Luchetti; Kevin D Beck; Manuel D Galvan; Richard Silva; Brian J Cummings; Aileen J Anderson
Journal:  J Neurotrauma       Date:  2010-02       Impact factor: 5.269

Review 10.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.